A share price of Tenaya Therapeutics Inc [TNYA] is currently trading at $0.71, up 1.64%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TNYA shares have gain 1.18% over the last week, with a monthly amount drifted -44.41%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Leerink Partners started tracking the stock with Outperform rating on November 30, 2023, and set its price target to $7. On June 15, 2022, H.C. Wainwright initiated with a Buy rating and assigned a price target of $25 on the stock.
Tenaya Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.36 and $2.35. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. Tenaya Therapeutics Inc [NASDAQ: TNYA] shares were valued at $0.71 at the most recent close of the market. An investor can expect a potential return of 322.54% based on the average TNYA price forecast.
Analyzing the TNYA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.9, Equity is -0.95 and Total Capital is -1.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6905 points at the first support level, and at 0.6695 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7220, and for the 2nd resistance point, it is at 0.7325.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Tenaya Therapeutics Inc [NASDAQ:TNYA] is 4.64. As well, the Quick Ratio is 4.64, while the Cash Ratio is 4.26.
Transactions by insiders
Recent insider trading involved Higa Tomohiro, SVP, Finance, that happened on Nov 17 ’25 when 1367.0 shares were sold. Chief Medical Officer, Tingley Whittemore completed a deal on Nov 17 ’25 to sell 2877.0 shares. Meanwhile, Chief Executive Officer Ali Faraz sold 3126.0 shares on Nov 17 ’25.
